NCT06239532 is a Phase 2 clinical trial of HAIC+TAE in Intrahepatic Cholangiocarcinoma, sponsored by Qilu Hospital of Shandong University.

Who is sponsoring NCT06239532?

NCT06239532 is sponsored by Qilu Hospital of Shandong University.

What drugs are being tested in NCT06239532?

Interventions in NCT06239532: HAIC+TAE, Tislelizumab, Surufatinib.

What condition does NCT06239532 study?

NCT06239532 studies Intrahepatic Cholangiocarcinoma.

Is NCT06239532 still recruiting?

NCT06239532 is currently active, enrolled. Last updated 21 November 2024.

Last reviewed 2024-11-21 · How we verify

NCT06239532

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Active, enrolled Phase 2 Last updated 21 November 2024

What this trial tests

Phase 2 trial testing HAIC+TAE in Intrahepatic Cholangiocarcinoma in 28 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

27 September 2022

Primary endpoint
31 December 2024

31 December 2025

Quick facts

Lead sponsor	Qilu Hospital of Shandong University
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	28
Start date	27 September 2022
Primary completion	31 December 2024
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

HAIC+TAE — full drug profile →
Tislelizumab (TISLELIZUMAB) — full drug profile →
Surufatinib — full drug profile →

Conditions studied

Intrahepatic Cholangiocarcinoma — all drugs for Intrahepatic Cholangiocarcinoma →

Sponsor

Qilu Hospital of Shandong University

Who can join

Adults 18 to 80, any sex, with Intrahepatic Cholangiocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single center, single arm, phase II, prospective study to evaluate the safety and effectiveness of HAIC combined with TAE plus an ICI and an TKI in adult patients (aged ≥18 years) with unresectable intrahepatic cholangiocarcinoma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challenges.
Liu JJ, Zhou M, Yuan T, Huang ZY, et al · · 2025 · cited 3× · PMID 40309227 · DOI 10.3748/wjg.v31.i15.104901
Protocol of REACH-01: a single-arm, open label, prospective study of HAIC sequential TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma.
Li KS, Liu Y, Zhang TZ, Xu YF, et al · · 2024 · cited 1× · PMID 39624833 · DOI 10.3389/fphar.2024.1435639

Verify or expand the search:

Other recruiting trials for Intrahepatic Cholangiocarcinoma

Currently open trials in the same condition.

NCT06990659 — Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC) · NA · recruiting
NCT06910722 — Liver Transplantation for Locally Advanced Intrahepatic Cholangiocarcinoma After SIRT and Chemotherapy · NA · recruiting
NCT07169734 — A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06664021 — Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperativ · Phase 2 · recruiting
NCT06505486 — GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC · recruiting

Other Qilu Hospital of Shandong University trials

Trials by the same sponsor.

NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting
NCT07140419 — Coronary Computed Tomographic Angiography Combined With CT-FFR in Intermediate-Risk Chest Pain Patients. · NA · not yet recruiting
NCT07509879 — Research on the Molecular Mechanism of Cognitive Differences Between Williams Syndrome and Autism Spectrum Disorder · not yet recruiting
NCT07537374 — A Case-Control Observational Study of Peripheral Blood-Derived iPSC Models to Investigate Oligodendrocyte Lineage Develo · not yet recruiting
NCT07505940 — Bilateral Comparison of Unilateral Sacral Neuromodulation Test Stimulation in the Treatment of Neurogenic Bladder · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06239532 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qilu Hospital of Shandong University
Last refreshed: 21 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06239532.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing